Philips Ramps Up US Production, Seeks To Swiftly Move On From New FDA Warning Letter

Improving inspection outcomes and strengthened US operations help company navigate trade pressures.

 
• By Shubham Singh
  
Philips does not expect any regulatory action as corrective measures progress alongside rising ultrasound demand and product launches. Picture Courtesy: Shutterstock

More from Strategy

More from Business